UPDATED on 2/12/2014
Nice job on CVD 1.
POINT #1:
CVD 1: Cover image:
The editor produced this image by applying dynamic magnetic resonance imaging to a patient with a patent foramen ovale. The 3D reconstruction shows blood movement in chambers of the heart, which includes a narrow funnel of shunt flow between left and right atrial chambers through an opening in a flap of tissue that normally seals a trap door called the foramen ovale. The foramen ovale provides a bypass of the lungs in utero.
Currently, this is the Cover IMAGE of Volume TWO in Series A, you are FIRST name of the Co-Curation e-Book. Please consider to yield this Image and its description to Volume TWO. Please find another one for CVD 1.
POINT #2:
Yes, what you did for CVD 1 need to be done SAME for
2.1 CVD 2
2.2 CVD 3
2.3 Series A: Volume SIX [it contains a lot of writing by you, thus MUST be in Italics]
2.4 Please check Series A: Volumes: 3,4,5,6 — ANY CONTENT YOU HAVE AUTHORED MUST be in Italics as VOICE of Content Consultant – UPON completion of Steps ONE and TWO, below
SUGGESTIONS:
Step ONE: Please carry over the changes made to CVD 1 to CVD 2 and CVD 3
Step TWO: Please updated placements from the Archive [1/12/2014 to Present] – into CVD 1,2,3
Step THREE: Please – [While CVD 1 has the Calcium Series Updated], PENDING remained for:
CVD 1,2,3 STILL needs to have been updated from SERIES A: Volumes 1,2,3,4,5,6 – Content created 1/10/2013 – to Present
POINT #3: Upon completion of Point #1 and #2, Please for each Volume, work as Author of the
- Introduction to the Three-Volume Series
- Introduction to each Volume
- Introduction and key words to Each Chapter
- Summary to each Chapter
- Summary and Epilogue to each volume
- Summary for the Three-Volume Series
POINT #4: Upon completion of POINT #3, Please work as Author on FOUR articles as Single Author
THANK YOU, I am happy that we are BACK on the RIGHT track.
I always meant that we need to improve the communication, I never meant anything but THAT.
____________________
Volumes 1,2,3,4,5,6 serve as
SOURCES for CVD 1,2,3
1/28/2014 – We are restoring CVD – ZERO as OUR communication Board
Please scroll down to the END, then back to the beginning.
Dr. Pearlman,
0. Since I appropriated the IMAGE of CVD 1 for Series A: Volume 2 — please suggest to me another Image for CVD 1. If you must have it for CVD 1, I will yield it to you, though Volume Two represents a concentration of 20 articles with your name, in one Volume !! Please advise on that matter.
1. YOU will find full record [article title, authors, link] for you to copy and paste,
just adding article ID — into CVD 1,2,3 by going to Series A: Volume # and article ID as below
EXAMPLE
2.1.1.1 V3 etiol – will have for you a ready made entry for CVD 1 etiol
2. Please find all articles for PLACEMENT in CVD 1.2.3 – all articles per each Volume FOR the period: 3/2013 – 1/12/2014
Thank you for your diligent searches and placements as Content Consultant to Series A and as Editor of CVD 1,2,3
3. VOICE of the Editor – in Italics BEFORE the article ID – for ALL articles
EXAMPLE
NOW it is like that:
1.3 CTEP, the enzyme responsible for chemical exchanges between triglycerides (dietary simple carbohydrate intake) and good cholesterol (HDL) can contribute to hardening of arteries. Conversely genetically low activity of CETP can confer longevity. CTEP mediates lowering of HDL due to dietary excesses of bread and other carbohydrates by chemical interactions triggered by high triglyceride levels. Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of Anacetrapib to treat Atherosclerosis and CAD |Comments»
It should be like that
CTEP, the enzyme responsible for chemical exchanges between triglycerides (dietary simple carbohydrate intake) and good cholesterol (HDL) can contribute to hardening of arteries. Conversely, genetically low expression (activity) of CETP can confer longevity. CTEP mediates lowering of HDL due to dietary excesses of bread and other carbohydrates by chemical interactions triggered by high triglyceride levels.
1.3 Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of Anacetrapib to treat Atherosclerosis and CAD |Comments»
Aviva Lev-Ari, PhD, RN
[Please, visit ALL Comments sections when Comments is mentioned in all articles in CVD 1,2,3 and decide which of the comments you wish to append to the article
NOT all comment are equally worthy to become integrated to articles, thus, the EDITOR of e-Books has VAST power of critical judgment on the content MERIT. The Editor is in tandem INTERFACE with the e-Reader and with the EAW and/or the Article Curator.
(Comments are not available in the soft/hard cover publishing world – Thus, If Editor find merit in them, he has to embed them at the end of the article).
THEN at the end of the article ADD section e-Readers Comment(s): copy and paste ONLY the comment(s) the EDITOR wishes to become part of the article]
ADD in the beginning of each volume, (along these lines)
Editorial decisions were made regarding the inclusion of e-Readers’ Comments for various articles. The Comments included, represent Editor’s selection of unique e-Reader insightful contribution to the subject and the discussion in the article.
Articles for PLACEMENT in CVD 1.2.3 –
all articles per each Volume for the period
3/2013 – 1/12/2014
CVD 1
CVD1 etiol] Smoking Status: Effects on Heart and Blood Vessels & Meta Data Analysis on Death from Lung Cancer
find full record to cite in 2.1.1.1 V3 etiol
CVD 1] Heart Tumors: Etiology and Classification ; Reporter: Aviva Lev-Ari, PhD, RN
find full record to cite in 2.1.5.3 V3 etiol
CVD1 gene] Atrial Fibrillation: IL6R Polymorphism in Whites and African Americans = Causation/Genetics/Risk/arrhythmia/AtrialFibrillation
In V3gene
CVD1 gene] Genetics of Hypertension in African Americans – Gene Association Study =Causation/Genetics/Risk/Hypertension
In 3.3.4.1 V3gene
[V3gene ; CVD1 gene] Atrial Fibrillation: IL6R Polymorphism in Whites and African Americans = Causation/Genetics/Risk/arrhythmia/AtrialFibrillation
[DONE 3.3.4.1 V3gene ; CVD1 gene] Genetics of Hypertension in African Americans – Gene Association Study =Causation/Genetics/Risk/Hypertension
[DONE 3.3.3.3 V3gene ; CVD1 gene]Genetics of Aortic and Carotid Calcification: The Role of Serum Lipids =Causation/Genetics/Risk/VascularDisease/Atherosclerosis
[DONE 3.3.3.1 V3gene ; CVD1 gene] Cardiometabolic Syndrome and the Genetics of Hypertension: The Neuroendocrine Transcriptome Control Points =Causation/genetics/hypertension/risk
[V3gene MENTIONED IN “3.3 Leading DIAGNOSES of Cardiovascular Diseases covered in Circulation” ; CVD1 gene] MicroRNA in Serum as Bimarker for Cardiovascular Pathologies: acute myocardial infarction, viral myocarditis, diastolic dysfunction, and acute heart failure =biomarkers/cardiomyopathy/heartFailure/MyocardialInfarction
[DONE 3.3.1.2 V3gene ; CVD1 gene] Common Heart Failure: Clinical Considerations of Heritable Factors =causes/heartFailure/genetics
[DONE 3.3.6.1 BUT SHOULD BE WITH 3.3.4.2 V3 gene; CVD1 arrhythm] Genetic Analysis of Atrial Fibrillation =Cause/Genetics/Arrhythmia/Electrophysiology/AtrialFibrillation
[V4 therapPromise; CVD1] Cardiac Contractility & Myocardium Performance: Therapeutic Implications for Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses =CALCIUM/CAUSE/HEART_FAILURE ***jdp
[put in 2.2.4 V3etiol, V4 therapPromise; CVD1 chf, CVD3 chf] Publications on Heart Failure by Prof. William Gregory Stevenson, M.D. = HeartFailure
[DONE 2.1.8.5 V3etiol, CVD1chf] Heart Smooth Muscle and Cardiomyocyte Cells: Excitation-Contraction Coupling & Ryanodine Receptor (RyR) type-1/type-2 in Cytoskeleton Cellular Dynamics and Ca2+ Signaling =CAUSE/HEART_FAILURE/BIOMARKERS/TREATMENT
[DONE was in 3.2 V3genetic, CVD1genetic] Cardiovascular Genetics: Functional Characterization and Clinical Applications @ 2013 Annual Conference of American Society of Human Genetics in Boston, 10/22-26, 2013 =GENETICS/SEPTAL_DEFECT/NON_COMPACTION/BRUGADA/ARRHYTHMIA/
[Put in 1.3 near 1.3.3 V3etiol, CVD1] Role of Calcium, the Actin Skeleton, and Lipid Structures in Signaling and Cell Motility = CALCIUM/CAUSE/
[put near 2.2.4.2 V3etiol, CVD1]The Cardio-Renal Syndrome (CRS) in Heart Failure (HF) =RISK/HEART_FAILURE
[V1 NEXT TO “1.6.1 Interaction of Nitric Oxide and Prostacyclin in Vascular Endothelium” NO, V4 therapy promise, CVD1] Prostacyclin and Nitric Oxide: Adventures in Vascular Biology – A Tale of Two Mediators CAUSE/VASCULAR/NITRIC_OXIDE
[in 3.3 but not by full name link V3, CVD1] Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013 =GENETICS/RISK
[Put in 1.4 V3, CVD1] Genomics Orientations for Individualized Medicine = GENETICS
[V4TherapeuticPromise match to 2.8.1, 2.8.3, 2.8.4, 2.8.7,2.8.10,2.8.11, CVD1-mito] Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation 745
to add CVD1
2013 as A Year of Revolutionizing Medicine and Top 11 Cardiology Stories
Aviva Lev-Ari, PhD, RN
3.2.8 Calcium Signaling, Cardiac Mitochondria and Metabolic Syndrome
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
—————————
CVD 2
CVD2 gene] Nicotinic Acetylcholine Receptor Genes with Subclinical Atherosclerosis in American Indians: Genetic Variants Study = Causation/Genetics/Risk/Biomarkers/Atherosclerosis
In 3.3.4.4 V3gene
CVD2 markers]Atherosclerosis Risk and Highly Sensitive Cardiac Troponin-T Levels in European Americans and Blacks: Genome-Wide Variation Association Study = Causation/Genetics/Risk/Biomarkers/Atherosclerosis
In 3.3.4.3 V3gene
[DONE ***with changed title*** 2.2.1.2 V3gene ; CVD2 biomark] Myocardial Damage in Cardiovascular Disease: Circulating MicroRNA-208b and MicroRNA-499
=biomarkers/cardiomyopathy/heartFailure/MyocardialInfarction
[put in 2.4 near 2.4.2 V3 etiol; CVD2 biomark] Diabetes-risk Forecasts: Serum Calcium in Upper-Normal Range (>2.5 mmol/L) as a New Biomarker = BIOMARKER
to add CVD2
4.2.12 Myocardial Infarction: The New Definition After Revascularization
Aviva Lev-Ari, PhD, RN
4.3.4 Renal Function Biomarker, β-trace protein (BTP) as a Novel Biomarker for Cardiac Risk Diagnosis in Patients with Atrial Fibrilation
Aviva Lev-Ari, PhD, RN
CVD 3
CVD3] Preventive Medicine Philosophy: Excercise vs. Drug, IF More of the First THEN Less of the Second
find full record to cite in V3 2.1.3.4
CVD3 htn or interven] Market Impact on Global Suppliers of Renal Denervation Systems by Pivotal US Trial: Metronics’ Symplicity Renal Denervation System FAILURE at Efficacy Endpoint
Record to cite in V6 interven
CVD3 tx reach] Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Record to cite in V3 2.1.5.6
, CVD3 pharm] Radiation and Chemotherapy Therapy: The Pharmacological Risk for Developing Cardiovascular Disease
[DONE 3.3.3.2 V3gene ; CVD3 gene] Gene Study of Blood Pressure Response to Dietary Potassium Intervention =Causation/Genetics/Hypertension/treatment
[V4 therapPromise V6 interven; CVD3 interven] Protected: Non-Hardware Mitral Annuloplasty – Dr. Pearlman Presentation to ValueCure on 11/5/2013 = treatment/valveDisease/invention
[DONE 2.8 V4 therapPromise; CVD3 cell/tissue] Neoangiogenic Effect of Grafting an Acellular 3-Dimensional Collagen Scaffold Onto Myocardium = treatment/heartFailure/MyocardialInfarction/TissueEngineering
[DONE inV4:2.7 but suggest V4:4.3 therapPromise 3.2; CVD3 cell/tissue] Source of Stem Cells to Ameliorate Damaged Myocardium = Treatment/HeartFailure/MyocardialInfarction
[ CVD3 pharm, CHF] Heroes in Medical Research: Dr. Carmine Paul Bianchi Pharmacologist, Leader, and Mentor =calcium
[DONE 2.6 V4 therap; CVD3 celltissue] Progenitor Cell Transplant for MI and Cardiogenesis = Treatment/CellTherapy/Tissue/HeartFailure
[DONE 1.2 V4translat; CVD3 translat] State of Cardiology on Wall Stress, Ventricular Workload and Myocardial Contractile Reserve: Aspects of Translational Medicine =TranslationMedicine/Cause/HeartFailure/Imaging
[DONE V2:2.2.3 BUT TITLE DIFFERS curation example ; CVD3delivery] Final Implementation of the Affordable Care Act and a Patient and Community Outcomes Focus = TREATMENT
[V6interven, CVD3] Call for the abandonment of the Off-pump CABG surgery (OPCAB) in the On-pump / Off-pump Debate, +100 Research Studies =TREATMENT/SURGERY
[V6interven, CVD3] Vasoplegia in Orthotopic Heart Transplant Patients =TREATMENT/SURGERY
[V6interven, CVD3] Mechanical Circulatory Assist Devices as a Bridge to Heart Transplantation or as “Destination Therapy“: Options for Patients in Advanced Heart Failure =TREATMENT/SURGERY/HEART_FAILURE
[V6interven, CVD3] Heart Transplantation: NHLBI’s Ten year Strategic Research Plan to Achieving Evidence-based Outcomes =TREATMENT/SURGERY/HEART_FAILURE/TRANSPLANT
[V6interven, CVD3] After Cardiac Transplantation: Sirolimus acts as immunosuppressant Attenuates Allograft Vasculopathy =TREATMENT/SURGERY/TRANSPLANT
[V6interven, CVD3] Orthotropic Heart Transplant (OHT): Effects of Autonomic Innervation / Denervation on Atrial Fibrillation (AF) Genesis and Maintenance =TREATMENT/SURGERY/TRANSPLANT
[V6interven, CVD3]CABG Survival in Multivessel Disease Patients: Comparison of Arterial Bypass Grafts vs Saphenous Venous Grafts =TREATMENT/RISK/SURGERY/CORONARY_DISEASE
[V6interven, CVD3]Coronary Reperfusion Therapies: CABG vs PCI – Mayo Clinic preprocedure Risk Score (MCRS) for Prediction of in-Hospital Mortality after CABG or PCI =TREATMENT/RISK/SURGERY/CORONARY
[UPDATE V1 – NO, V4 therapy next to 2.6.4, CVD3]Transposon-mediated Gene Therapy improves Pulmonary Hemodynamics and attenuates Right Ventricular Hypertrophy: eNOS gene therapy reduces Pulmonary vascular remodeling and Arterial wall hyperplasia =NITRIC_OXIDE/HEART_FAILURE/PULMONARY_HYPERTENSION/TREATMENT
[V6interven,CVD3interven]First-of-Its-Kind FDA Approval for ‘AUI’ Device with Endurant II AAA Stent Graft: Medtronic Expands in Endovascular Aortic Repair in the United States =TREATMENT/VASCULAR
[V6interven,CVD3interven]Bioabsorbable Drug Coating Scaffolds, Stents and Dual Antiplatelet Therapy = TREATMENT/TISSUE/ANTIPLATELET
[V6 interven, CVD3] Treatment of Refractory Hypertension via Percutaneous Renal Denervation 892
DO NOT USE, Please [V4, CVD3] Future of Calcitonin…? 889
[V4Translational,CVD3 dis mgt] Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers 864
[V5Pharm, CVD3]‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly 848
DO NOT USE, Please [V5Pharm] The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) – can affect heart 805
The CALCIUM Series consists of the following TWELVE articles: Please UNPACK the series for inclusion in each of CVD 1,2,3 [some are in, some changed part number]
Calcium and Cardiovascular Diseases: A Series of Twelve Articles in Advanced Cardiology
Curator: Aviva Lev-Ari, PhD, RN
Identification of Biomarkers that are Related to the Actin Cytoskeleton – Part I
Larry H Bernstein, MD, FCAP
Role of Calcium, the Actin Skeleton, and Lipid Structures in Signaling and Cell Motility – Part II
Larry H. Bernstein, MD, FCAP, Stephen Williams, PhD and Aviva Lev-Ari, PhD, RN
Renal Distal Tubular Ca2+ Exchange Mechanism in Health and Disease – Part III
Larry H. Bernstein, MD, FCAP, Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN
Larry H Bernstein, MD, FCAP, Justin Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
Justin Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Justin Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Justin Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Sensors and Signaling in Oxidative Stress – Part XI
Larry H. Bernstein, MD, FCAP
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Leave a Reply